Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TKNO 
Alpha Teknova Inc (TKNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TKNO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10
1 Year Target Price $10
| 3 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.17% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 238.14M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 5 | Beta 0.33 | 52 Weeks Range 4.00 - 10.37 | Updated Date 08/29/2025 |
52 Weeks Range 4.00 - 10.37 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.0996 | Actual -0.07 |
Profitability
Profit Margin -55.24% | Operating Margin (TTM) -32.92% |
Management Effectiveness
Return on Assets (TTM) -11.8% | Return on Equity (TTM) -27.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 235620369 | Price to Sales(TTM) 6.12 |
Enterprise Value 235620369 | Price to Sales(TTM) 6.12 | ||
Enterprise Value to Revenue 6.05 | Enterprise Value to EBITDA -6.23 | Shares Outstanding 53515200 | Shares Floating 10346622 |
Shares Outstanding 53515200 | Shares Floating 10346622 | ||
Percent Insiders 10.82 | Percent Institutions 85.21 |
Upturn AI SWOT
Alpha Teknova Inc
Company Overview
History and Background
Alpha Teknova, Inc. was founded in 1975. It initially focused on providing custom media and reagents for cell culture. Over time, it expanded its product offerings to include a broad range of tools for genomic research, protein analysis, and cell biology. The company went public in 2021.
Core Business Areas
- Genomics: Offers reagents and kits for DNA and RNA manipulation, sequencing, and PCR. This includes products for library preparation, amplification, and labeling.
- Cell Biology: Provides cell culture media, supplements, and reagents for cell growth, differentiation, and analysis. Products cover areas like cell signaling, apoptosis, and cell cycle research.
- Proteomics: Offers reagents and kits for protein extraction, purification, and analysis. Includes products for electrophoresis, western blotting, and ELISA.
- Custom Solutions: Provides custom formulations and manufacturing services to meet specific research needs. This includes custom media, buffers, and reagents.
Leadership and Structure
The company is led by a CEO and a management team overseeing various departments like R&D, Sales, Marketing, and Operations. The organizational structure is hierarchical, with teams reporting to department heads who then report to executive leadership.
Top Products and Market Share
Key Offerings
- Custom Media: Custom-formulated cell culture media tailored to specific customer requirements. Alpha Teknova competes with Thermo Fisher Scientific and Cytiva in this space. Precise revenue and market share data are not publicly available; however, it's a significant revenue driver.
- Molecular Biology Reagents: A wide array of reagents including buffers, enzymes, and kits used in PCR, qPCR, and DNA/RNA purification. Competitors include QIAGEN, New England Biolabs (NEB), and Roche. Revenue contributions and market share aren't explicitly disclosed, but contribute significantly.
Market Dynamics
Industry Overview
The life science tools and reagents market is experiencing robust growth driven by increasing research funding, advancements in genomics and proteomics, and the rising prevalence of chronic diseases. The market is competitive, with many players ranging from large corporations to specialized niche companies.
Positioning
Alpha Teknova is positioned as a provider of high-quality, customizable solutions for the life science research market. Their competitive advantage lies in their ability to provide tailored products and services, quick turnaround times, and strong customer support.
Total Addressable Market (TAM)
The global life science tools and reagents market is estimated to be in the range of $80-100 billion. Alpha Teknova addresses specific segments within this TAM, including cell culture, genomics, and proteomics reagents. Given its relatively smaller size compared to major players, Alpha Teknova currently captures a small percentage of this TAM, but with growth potential.
Upturn SWOT Analysis
Strengths
- Customization capabilities
- Strong customer support
- Rapid product development
- High-quality products
Weaknesses
- Smaller market share compared to larger competitors
- Limited brand recognition
- Potential supply chain vulnerabilities
- Reliance on research funding trends
Opportunities
- Expanding product portfolio
- Geographic expansion
- Strategic partnerships and acquisitions
- Increasing demand for personalized medicine
Threats
- Intense competition
- Price pressure
- Changes in regulatory landscape
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ILMN
- QGEN
- NEB
Competitive Landscape
Alpha Teknova operates in a highly competitive market dominated by larger players with greater resources. While Alpha Teknova's strengths lie in its customization and customer service, it faces challenges in competing on price and scale.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires recent financial data not yet available. Placeholders are used
Future Projections: Future projections requires analysts estimations not yet readily available. Placeholders are used
Recent Initiatives: Recent strategic initiatives require financial data and future guidance not readily available. Placeholders are used.
Summary
Alpha Teknova is a smaller player in a large market with strong customization capabilities. It needs to continue innovating and expanding its product portfolio to compete effectively. It should consider strategic partnerships and acquisitions to increase its market presence. Maintaining customer satisfaction is key for continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is estimated. Financial data placeholders are present due to lack of recent data availability.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Teknova Inc
Exchange NASDAQ | Headquaters Hollister, CA, United States | ||
IPO Launch date 2021-06-25 | President, CEO & Director Mr. Stephen Gunstream | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 173 | Website https://www.teknova.com |
Full time employees 173 | Website https://www.teknova.com | ||
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.